Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. … Read more
Luoxin Pharmaceuticals Group Stock Co Ltd (002793) - Total Assets
Latest total assets as of September 2025: CN¥3.99 Billion CNY
Based on the latest financial reports, Luoxin Pharmaceuticals Group Stock Co Ltd (002793) holds total assets worth CN¥3.99 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Luoxin Pharmaceuticals Group Stock Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Luoxin Pharmaceuticals Group Stock Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Luoxin Pharmaceuticals Group Stock Co Ltd's total assets of CN¥3.99 Billion consist of 41.2% current assets and 58.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.5% |
| Accounts Receivable | CN¥662.93 Million | 15.3% |
| Inventory | CN¥459.56 Million | 10.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥674.40 Million | 15.6% |
| Goodwill | CN¥1.95 Million | 0.1% |
Asset Composition Trend (2011–2024)
This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Luoxin Pharmaceuticals Group Stock Co Ltd's current assets represent 41.2% of total assets in 2024, a decrease from 75.2% in 2011.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, down from 24.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 2.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 15.6% of total assets.
Luoxin Pharmaceuticals Group Stock Co Ltd Competitors by Total Assets
Key competitors of Luoxin Pharmaceuticals Group Stock Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Luoxin Pharmaceuticals Group Stock Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Luoxin Pharmaceuticals Group Stock Co Ltd generates 0.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Luoxin Pharmaceuticals Group Stock Co Ltd is currently not profitable relative to its asset base.
Luoxin Pharmaceuticals Group Stock Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.81 | 0.85 | 1.65 |
| Quick Ratio | 0.64 | 0.63 | 1.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-384.24 Million | CN¥ -363.12 Million | CN¥ 1.91 Billion |
Luoxin Pharmaceuticals Group Stock Co Ltd - Advanced Valuation Insights
This section examines the relationship between Luoxin Pharmaceuticals Group Stock Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.64 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -15.3% |
| Total Assets | CN¥4.34 Billion |
| Market Capitalization | $409.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Luoxin Pharmaceuticals Group Stock Co Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Luoxin Pharmaceuticals Group Stock Co Ltd's assets decreased by 15.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2024)
The table below shows the annual total assets of Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.34 Billion | -15.27% |
| 2023-12-31 | CN¥5.12 Billion | -36.88% |
| 2022-12-31 | CN¥8.11 Billion | -14.63% |
| 2021-12-31 | CN¥9.50 Billion | +22.99% |
| 2020-12-31 | CN¥7.72 Billion | +3.50% |
| 2019-12-31 | CN¥7.46 Billion | +432.24% |
| 2018-12-31 | CN¥1.40 Billion | +55.93% |
| 2017-12-31 | CN¥898.93 Million | +10.58% |
| 2016-12-31 | CN¥812.89 Million | +47.91% |
| 2015-12-31 | CN¥549.60 Million | +22.72% |
| 2014-12-31 | CN¥447.86 Million | +23.28% |
| 2013-12-31 | CN¥363.30 Million | -2.42% |
| 2012-12-31 | CN¥372.31 Million | +36.91% |
| 2011-12-31 | CN¥271.94 Million | -- |